A Canadian company is trying to revive a rare cancer drug that’s been out of stock since the mid-1990s.
The company, Emerald Health Pharmaceuticals, says it has developed a way to produce a new generation of its drug from stem cells in the body.
Emerald said it hopes to have the drug on the market within the next six months.
In 2015, the company was sued by former Emerald employee Jennifer LeBlanc, who alleged that her former employer had misappropriated her time and funds and illegally pressured her into signing a non-disclosure agreement.
LeBlanz alleged she was misled by the company and a senior Emerald executive.
The case is still before the courts.
With files from John Ibbitson, The Canadian Press